Qube Research & Technologies (QRT)
CNTX icon

Qube Research & Technologies (QRT)’s Context Therapeutics CNTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
257,068
+245,670
+2,155% +$498K ﹤0.01% 2971
2026
Q1 		$29.9K Buy
+11,398
New +$26.6K ﹤0.01% 3241
2025
Q4 		– Sell
-82,111
Closed -$79.5K – 3717
2025
Q3 		$79.5K Sell
82,111
-24,668
-23% -$20K ﹤0.01% 3108
2025
Q2 		$70K Sell
106,779
-67,530
-39% -$48.6K ﹤0.01% 3095
2025
Q1 		$107K Sell
174,309
-148,529
-46% -$129K ﹤0.01% 2995
2024
Q4 		$339K Buy
322,838
+219,433
+212% +$380K ﹤0.01% 2651
2024
Q3 		$203K Buy
+103,405
New +$229K ﹤0.01% 2582

Other funds holding CNTX

Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Nextech Invest
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Avidity Partners Management
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Octagon Capital Advisors
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CNTX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Context Therapeutics (CNTX) stake by 2,155% in Q2 2026, buying an estimated $498K and bringing the position to 257,068 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #2971.

Qube Research & Technologies (QRT) first reported a position in CNTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $339K in Q4 2024. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Qube Research & Technologies (QRT) held 257,068 shares of Context Therapeutics worth $142K as of Q2 2026.
  • Qube Research & Technologies (QRT) bought 245,670 Context Therapeutics shares in Q2 2026, an estimated $498K.
  • Context Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #2971 holding.
  • Qube Research & Technologies (QRT) first reported a position in Context Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Qube Research & Technologies (QRT)'s Context Therapeutics position peaked at $339K in Q4 2024.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.